Compare Charles River Laboratories Intl. Inc (CRL) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs S&P Global Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while S&P Global Inc trades at $439.99 (market cap $129.91B). The key difference: S&P Global Inc is far larger — about 11.7× Charles River Laboratories Intl. Inc's market cap, and S&P Global Inc pays a 0.88% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SPGI | |
|---|---|---|
Market Cap | $11.14B | $129.91B |
Sector | Health | Financials |
52-Week High | $233.60 | $534.79 |
52-Week Low | $145.57 | $370.42 |
Enterprise Value | $14.00B | $141.87B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
S&P Global (SPGI) trades at $437.84, up 1.7% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $15.34B and net income margin of 30.36%. Recent developments include the completion of the Mobility Global spinoff and a strategic shift toward AI-driven market intelligence solutions, positioning the company for sustained growth amid favorable debt issuance trends.
The outlook for SPGI is positive, driven by margin expansion targets and increasing API usage linked to AI adoption. Key risks include interest rate sensitivity in the ratings segment and competitive pressures. With 85.7% of analysts rating it a Buy and a consensus price target of $532.38, the stock offers significant upside potential, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
